Cargando…

Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity

5-Fluorouracil (5-FU) remains to be the backbone of chemotherapy regimens approved for treatment of colorectal cancer and other gastrointestinal cancers and breast cancer. The incidence of cardiotoxicity associated with 5-FU ranges from 1.5–18%. Previous studies also concluded that rechallenging a p...

Descripción completa

Detalles Bibliográficos
Autor principal:	Saif, Muhammad Wasif
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553662/ https://www.ncbi.nlm.nih.gov/pubmed/33116601 http://dx.doi.org/10.2147/OTT.S264156

Ejemplares similares

Safety and Efficacy of s-MOX Regimen in Patients with Colorectal Cancer Who Developed Cardiotoxicity Following Fluoropyrimidine Administration: A Case Series
por: Ehrlich, Matthew I., et al.
Publicado: (2020)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Selecting treatment options in refractory metastatic colorectal cancer
por: Byrne, Margaret, et al.
Publicado: (2019)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)
por: Lombardi, Pasquale, et al.
Publicado: (2022)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
por: Jurczyk, Michał, et al.
Publicado: (2021)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer
por: Saif, Muhammad Wasif
Publicado: (2012)

Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: A retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity
por: Wang, Yan, et al.
Publicado: (2023)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

Rechallenging Fluoropyrimidine-Induced Cardiotoxicity and Neurotoxicity: A Report of Two Cases
por: Ashish, Sethi, et al.
Publicado: (2022)

Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report
por: Peng, Tao, et al.
Publicado: (2019)

Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis
por: Lu, Yajie, et al.
Publicado: (2023)

Recurrent cardiotoxicity in a fluoropyrimidine treated cancer patient – case report and practical recommendations
por: Deac, Andrada Larisa, et al.
Publicado: (2023)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
por: Saif, Muhammad Wasif
Publicado: (2013)

Fluoropyrimidine Modulation of the Anti-Tumor Immune Response―Prospects for Improved Colorectal Cancer Treatment
por: Gmeiner, William H.
Publicado: (2020)

Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants
por: Raber, Inbar, et al.
Publicado: (2020)

Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases
por: Saif, Muhammad Wasif
Publicado: (2014)

Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration
por: Wu, Fengpeng, et al.
Publicado: (2021)

Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment
por: Das, Srijit, et al.
Publicado: (2022)

Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment
por: Anaka, Matthew, et al.
Publicado: (2022)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy
por: Schwarzenbach, Heidi
Publicado: (2010)

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
por: Saif, Muhammad Wasif, et al.
Publicado: (2020)

Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?
por: Twelves, C J, et al.
Publicado: (2002)

A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
por: Deac, Andrada-Larisa, et al.
Publicado: (2020)

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
por: Li, Jia, et al.
Publicado: (2009)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

MicroRNAs in Cancer Treatment-Induced Cardiotoxicity
por: Pellegrini, Laura, et al.
Publicado: (2020)

Genetic factors affecting patient responses to pancreatic cancer treatment
por: Fotopoulos, George, et al.
Publicado: (2016)

The Clinical Significance of Promoter Methylation of Fluoropyrimidine Metabolizing and Cyclooxygenase Genes in Colorectal Cancer
por: Fouad, Mariam Ahmed, et al.
Publicado: (2021)

Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
por: KÃ¶hne, C. H., et al.
Publicado: (1998)

Targeting cancers in the gastrointestinal tract: role of capecitabine
por: Saif, Muhammad Wasif
Publicado: (2009)

Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines
por: Jennings, Barbara A., et al.
Publicado: (2013)

Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer
por: Leonard, R C F
Publicado: (2001)

The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease
por: Fabin, Natalia, et al.
Publicado: (2022)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Cardiotoxicity Following Cancer Treatment
por: Walls, GM, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_trslgo76e5je2pmqd06252m5uj